BridgeBio Pharma, Inc. (NASDAQ: BBIO) shares are facing a steep pre-market decline of 11.40% on Wednesday, extending Tuesday's 14.06% drop, as investors continue to react negatively to the company's second-quarter 2025 financial results.

The biopharmaceutical company reported a loss of $0.95 per share for Q2 2025, significantly missing the analyst consensus estimate of $0.81 per share. This represents a 17.43% larger loss than expected and only a slight improvement from the $1.06 per share loss in the same quarter last year. The company's net loss attributable to common stockholders increased substantially to $181.9 million, compared to $73.5 million in Q2 2024.

Despite the disappointing bottom line, BridgeBio's top-line performance showed promise, with quarterly revenue of $110.6 million beating analyst expectations of $100.4 million by 10.10%. This marks a substantial increase from the $2.17 million reported in the same period last year, driven largely by $71.5 million in U.S. Attruby net product revenue. However, the market appears to be focusing on the widening losses, contributing to the continued downward pressure on the stock price in pre-market trading.